Raising Biotech的动态

Thrilled to share that Raising Biotech is now part of the Health Podcast Network! ?? Big shoutout to Daniel Couchman Kendall for creating such an outstanding community of top-tier, health-focused podcasts. It’s an incredible honor to be invited to join this group! Following the success of our first two seasons (12 episodes), we’re working away on the next chapter. In the meantime, if you missed any episodes, now’s the perfect time to catch up! ?? ?? ?? While some of the featured companies have since announced exciting news and updates, each episode remains an "evergreen" exploration of the unique origins and journeys of these promising biotechs -- each of which is securing impressive funding to drive ambitious medical breakthroughs. ?????? Season 1 ???: 1. Empress Therapeutics - cracking the code to novel small molecules 2. Ochre Bio - tackling chronic liver disease with human liver models 3. eGenesis, Inc. - breakthroughs with pig kidneys for human transplant 4. Synchron - brain implants allowing thoughts to control a digital device 5. Arialys Therapeutics, Inc. - tackling autoimmune neuropsychiatric diseases 6. Alltrna - leveraging tRNA therapeutics for ultra rare diseases Season 2 ???: 1. Mana.bio - programmable delivery of lipid nanoparticles 2. Fauna Bio - applying animal biology to human drug development 3. Ray Therapeutics, Inc. - restoring vision with optogenetics 4. Sparrow Pharmaceuticals, Inc. - solving the 75-year old steroid problem 5. Cerevance - a new approach to treating Parkinson's disease 6. iOmx Therapeutics AG - shaking up the immuno-oncology field ??: Listen to all these episodes on the Health Podcast Network, Apple, Spotify or wherever you listen! https://lnkd.in/eReD-fwt #biotech #financing #innovation #entrepreneur #healthpodcastnetwork

Following ISPOR 2024, we're re-listening to Bioverge Ventures’ founder Neil Littman sharing VC insights into healthcare and the life sciences on Dr. Chris Stout’s Living a Life in Full podcast. “What was once deemed to be science fiction is now increasingly becoming science fact,” he said.?“I firmly believe the next great revolution will be in the tools to re-architect our biology, our brains, our chemistry and ourselves. We are already seeing this play out in real time.” A key step along the way is to democratize access for a wider circle of investors to promising biotech deals, and to identify early on those startups which have the potential to contribute the most to patient needs. In order to select the latter, meticulous research and due diligence are paramount. "If I am intellectually honest, I have no idea a priori which one of our portfolio companies is going to have a billion-dollar outcome, but I need to have a relentless focus on the process to ensure we are investing in the right types of companies to give ourselves that statistical probability of success,” Littman added. We created our AI-powered PROVEN platform to help innovators as well as investors model uncertainty with unprecedented accuracy and flexibility and to gauge the value of any potential future treatment. To learn more about our innovative methodology, do not hesitate to reach out. Check out the full podcast here for more insights, including tips how to best manage the potentially complex relationship between VC investors and biotech founders, and a valuable perspective into how an investor’s well-curated network can contribute in diverse ways to the success of an early stage company: https://lnkd.in/dMPF7TSm? #HEOR #DrugPricing #BioPharma #Innovation?

In this week’s podcast ?? -?Neil Williams, Head of LeifBridge Investment Services, Ernst Knacke, Head of Investment Research, and Julian Wheeler, in-house US-Equity Specialist discuss the impact of technology and innovation on healthcare costs, the role of artificial intelligence in drug and molecule discovery, and the valuation disparities between biotech and big pharma. Topics include: ?? Exploring Healthcare Investment Opportunities ?? The Value Proposition of Healthcare Investments ??Innovation and AI in Healthcare ??Addressing the Risks in Healthcare Sector Investments ?? Spotlight on Weight Loss Drugs and Market Dynamics ?? Diving into Specific Investment Opportunities ?? Healthcare Investment Strategies Listen in on the conversion below ???? #healthcare #biotech #podcast

Pioneers is back with the second part of our recent podcast with Paul Grand of MedTech Innovator. In this half: -Challenges faced by MedTech startups, including lack of guidance and funding. (04:16) -MedTech Innovation ecosystem, including peers, key opinion leaders, investors, strategic partners, and payers. (07:02) -The value of working with a partner like Siemens. (14:05) -The importance of getting out of echo chambers and seeing different perspectives. (20:20) And more! Listen in here: ?? https://sie.ag/2PLCAZ ??

Pioneers is back with the second part of our recent podcast with Paul Grand of MedTech Innovator. In this half: -Challenges faced by MedTech startups, including lack of guidance and funding. (04:16) -MedTech Innovation ecosystem, including peers, key opinion leaders, investors, strategic partners, and payers. (07:02) -The value of working with a partner like Siemens. (14:05) -The importance of getting out of echo chambers and seeing different perspectives. (20:20) And more! Listen in here: ?? https://sie.ag/2PLCAZ ??

? 29 ????????????????, 29 ???????????????????? ?????????????? & ???????????? ??????????!?? Hosting The BioHub Podcast has been an amazing journey. Not only have I learned so much, but some key themes keep emerging from my conversations with top biotech and pharma leaders. Here are the topics that come up time and time again: ?? ????: ?????? ????????????????’?? ???????????????? Yes, it’s that buzzword again—AI! Everyone’s talking about it, trying to understand it, and figuring out how to get ahead with it. From drug discovery to data management, AI is changing the game for biotech. Want a deep dive into AI? Check out Episode 16 with Angelo Stracquatanio III—we explore how AI is reshaping the industry. ?? ?????????????? ???????? ???????????????? ?????? ?????????????????? With layoffs, funding challenges, and more, it’s a tough time for many in biotech. But the message is clear: To keep your best people, you need to create a great environment where they can thrive. Culture is key—especially when things get tough. ?? ?????? ???? ???????? ???? ???? ???????? ?????????? Find your passion, work for what you believe in, and if you’re not doing that, find a way to understand why your work matters. Meet your patients, connect with the impact—that’s what keeps the drive alive. ?? ???????????????? ???????? ???? ???????? In a time of tight financing, if you don’t have clinical data, you need rock-solid preclinical science and big names behind you. But let’s be honest—clinical data is still the trump card! Companies with exceptional data and proven results are the ones winning in this tough market. ????????? ?????? ???????? ???? ?????? ????????? Some VCs may have hit pause, but they’re starting to come back—and that’s a huge win for early-stage innovation. There’s still optimism out there, and we need that drive from startups to push boundaries and fuel progress. ?? ?????????????? ???? ???????????? ?? ?????????????????????????? If there’s one thing that’s certain, it’s that biotech is a wild ride. Every exec I’ve spoken to has their own stories of challenges and wins. It’s part of what makes biotech so exciting—never a dull moment! What does everyone think? Have I missed some big ones? #BioTech #Pharma #AI #CultureMatters #ClinicalData #VC #BiotechInnovation #TheBioHub

Pioneers is back with the second part of our recent podcast with Paul Grand of MedTech Innovator. In this half: -Challenges faced by MedTech startups, including lack of guidance and funding. (04:16) -MedTech Innovation ecosystem, including peers, key opinion leaders, investors, strategic partners, and payers. (07:02) -The value of working with a partner like Siemens. (14:05) -The importance of getting out of echo chambers and seeing different perspectives. (20:20) And more! Listen in here: ?? https://sie.ag/2PLCAZ ??

???"I had an advisor who said to me when I was a young scientist: 'I hope you are prepared for it to be twenty years before you see your invention make it to patients'. At the time I remember thinking it was fine, but, when you start to live the process, it can be tough because you really want to see the impact. For me that desire to be closer to patients, to physicians, and to patient impact is what brought me to MedTech." Listen to Sandra Waugh Ruggles, Stanford Biodesign’s director of policy research, in conversation with Shannon Lantzy, in this episode of Inside MedTech Innovation. They discuss how long it takes to get from FDA clearance to Medicare coverage, how regulatory innovation can fast-track disruptive technologies, and Sandra’s journey from biotech to MedTech. ??Link to podcast: https://lnkd.in/eQqgdXTG

Bright spot in a volatile market: Healthcare investment booms Even as economic uncertainty swirls, there's a beacon of hope in the early-stage investing world: healthcare. According to Carta data, startups in biotech, pharmaceuticals, and digital therapeutics are raking in more capital now than pre-pandemic! This trend highlights a few key points: Resilient demand: People will always prioritize their health, making healthcare a defensive investment even in downturns. Innovation on the rise: Advancements in these fields are creating exciting new solutions and attracting investor interest. Tech + health = : The convergence of technology and healthcare is a goldmine for investors seeking high-growth potential. Are you following the healthcare investment space? What trends are you most excited about? #healthcare #biotech #pharma #digitaltherapeutics #earlystageinvesting

Even in turbulent times, early-stage investing has held up in one particular area: Healthcare. Carta data shows biotech, pharmaceutical, and digital therapeutic startups are receiving more capital now than before the pandemic. In this week’s episode of The Data Minute, Peter Walker sits down with Marissa Bertorelli of Polaris Partners to discuss trends in early-stage healthcare investing. Listen here: https://lnkd.in/dXB35vGD Marissa and Peter answer questions like: ?? Can you found a healthtech company without being a scientist? ?? Do healthtech founders waste time pitching generalist funds? ?? How is AI being applied to healthtech startups? ?? Subscribe to get new episodes in your podcast feed every other week.